Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Lopinavir / ritonavir (Kaletra®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old. |
|||
|
|||
Medicine details |
|||
| Medicine name | lopinavir/ritonavir (Kaletra®) | ||
| Formulation | 80 mg/20 mg oral solution | ||
| Reference number | 3557 | ||
| Indication | Treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0218 | ||
| NMG meeting date | 10/01/2018 | ||
| AWMSG meeting date | 14/02/2018 | ||
| Date of issue | 05/03/2018 | ||
| Date of last review | March 2021 | ||